Insulet chief saw $2.3M in stock option exercises in
Insulet Corp. Chief Executive Duane DeSisto realized $2.3 million from stock option exercises last year as he leads the company’s expansion in the insulin market.
DeSisto’s gains came from exercising options on 100,000 shares of the company’s stock, the Bedford, Mass.-based company said in a regulatory filing.
Insulet shares are down 25 percent this year, but over the last week they’ve rallied, surging 17 percent.
Insulet’s chief product is the OmniPod Insulin Management System. The company’s sales more than doubled in the fourth quarter to $4.4 million. But Insulet is still losing money, posting a $15.7 million net loss in the fourth quarter, compared to a $10.9 million net loss in the year-ago quarter payday loan cash advance loan.
For 2008, Insulet projects revenue of $40 million to $45 million. Its net operating loss is expected to be $55 million to $60 million, with positive quarterly gross margins by the fourth quarter of 2008.
The company plans to accelerate manufacturing capacity and has said it will increase its investment in its sales force.
Last year, Insulet increased the base salary for DeSisto, 53, to $325,000 from $300,000, according to regulatory filings.